REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2012

Mar 27, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2012-03-26

Reporting Person: YANCOPOULOS GEORGE (Director, EVP CSO President Regeneron Re)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-03-26	Common Stock	S	32140	$120.21	Disposed	867216	Direct
2012-03-26	Common Stock	S	1010	$121.09	Disposed	866206	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	5534	Indirect

Footnotes

F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F2: Represents volume-weighted average price of sales of 32,140 shares of Company stock on March 26, 2012 at prices ranging from $120.00 to $120.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 26, 2012 at each separate price.

F3: Represents volume-weighted average price of sales of 1,010 shares of Company stock on March 26, 2012 at prices ranging from $121.00 to $121.32. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 26, 2012 at each separate price.